Johnson & Johnson has entered into a definitive agreement with Numab Therapeutics to acquire its wholly-owned subsidiary for the global rights to a novel, investigational first-in-class bispecific antibody, NM26, in an all-cash transaction of approximately $1.25 billion. NM26 targets two clinically proven pathways, IL-4R alpha subunit (IL-4Rα) and IL-31, in atopic dermatitis and has the potential to deliver transformational efficacy for patients living with immune mediated diseases.